Yuhan (000100.KS) Stock Price
Yuhan Price
Over the last 19 years Yuhan grew revenue by 9.0% annually, reaching 2.19 T KRW. Earnings per share have grown at 5.9% per year over the last 19 years. For Yuhan, the net margin of 8.9% is up versus 6.1% a few years ago. At today's price the dividend yield works out to roughly 0.58%. The payout ratio is around 28% of earnings. The dividend has grown at 8.5% per year over the past 19 years. The consensus 12-month price target for Yuhan is 151,980.00 KRW, about 76.3% above where the stock trades today. Of 20 analysts, 16 rate the stock a buy — an overall Buy consensus.
Yuhan stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Yuhan business model & stock analysis
Frequently asked questions about Yuhan
The business model of Yuhan Corp revolves around its core operations in the pharmaceutical industry. As a leading South Korean company, Yuhan Corp focuses on researching, developing, manufacturing, and marketing various pharmaceutical products. Its diverse portfolio includes prescription drugs, over-the-counter medications, and medical devices. By combining innovation, cutting-edge technology, and strategic partnerships, Yuhan Corp aims to address unmet medical needs and improve the overall health and well-being of individuals. With a strong emphasis on research and development, the company continually strives to deliver high-quality and effective healthcare solutions to customers worldwide.
Yuhan Corp is primarily active in the pharmaceutical industry.
The main competitors of Yuhan Corp in the market include Hanmi Pharmaceutical Co., Ltd., CJ Healthcare Corp., and Daewoong Pharmaceutical Co., Ltd.
Yuhan Corp, a leading pharmaceutical company, has a rich and extensive history. Established in 1926, it has grown to become an integral part of the healthcare industry in South Korea. Over the years, Yuhan Corp has been committed to enhancing the well-being of individuals through innovative and high-quality healthcare products. With a diverse product portfolio covering areas such as pharmaceuticals, animal health, and personal care, Yuhan Corp has established itself as a trusted brand both domestically and internationally. Continuously adapting to market demands and leveraging its research and development capabilities, Yuhan Corp strives to contribute to the improvement of global healthcare.
Yuhan Corp has achieved several significant milestones throughout its history. Some noteworthy achievements include the successful development and launch of innovative pharmaceutical products in various therapeutic areas. The company has also established strategic partnerships with global pharmaceutical organizations, expanding its global presence and promoting international collaborations. Yuhan Corp's commitment to research and development has resulted in groundbreaking advancements and the introduction of cutting-edge technologies. Additionally, it has received recognition for its sustainable business practices and contributions to societal welfare. Overall, Yuhan Corp's remarkable milestones highlight its dedication to advancing healthcare and its continuous pursuit of excellence in the pharmaceutical industry.
Yuhan Corp is primarily present in South Korea.
Yuhan Corp represents values and corporate philosophy centered around innovation, excellence, and ethical business practices. As a leading pharmaceutical and chemical company in South Korea, Yuhan Corp strives to provide innovative solutions for various healthcare needs. With a strong commitment to research and development, the company aims to enhance the quality of life by developing and commercializing safe and effective pharmaceutical products. Yuhan Corp also emphasizes sustainability and corporate social responsibility, aiming to contribute to a healthier society and environment. With a focus on customer satisfaction and continuous improvement, Yuhan Corp remains dedicated to delivering value and advancing the healthcare industry.
Analysts currently set an average price target of 140,165.00 KRW for the Yuhan stock (median: 151,980.00 KRW), implying +62.6 % versus the latest price. The consensus is based on 20 analyst ratings.
22 analysts currently rate the Yuhan stock: 18 recommend buying, 1 holding and 3 selling. For 2026, analysts expect Yuhan to generate revenue of 2.33 T KRW and earnings per share of 2,626.88 KRW.
Converted at the current exchange rate, the Yuhan share trades at 57.86 EUR (86,200.00 KRW).
The Yuhan share (000100.KS) is listed on 1 stock exchanges, including: KOSPI (Seoul) (000100.KS).
Yuhan Corporation is a South Korean company that was founded in 1926 and operates in various business sectors. The company is active in the pharmaceutical, health & wellness, and chemical industries. Pharmaceuticals Yuhan Corp primarily focuses on the development and manufacturing of innovative drugs, particularly for the treatment of cancer and neurological diseases. The company is able to effectively conduct research and development as over half of its employees work in this field. In addition to the pharmaceutical industry, the company also works as a distributor for international pharmaceutical companies such as Eli Lilly and Sanofi. Health & Wellness Yuhan Corp is also active in the health and wellness industry. The company operates a comprehensive health center and offers a variety of services and products to promote the health of customers and patients. The products offered include dietary supplements, health drinks, and personal care products. Chemicals Yuhan Corp also has a business segment for chemical products. The company produces a variety of chemicals, particularly for the manufacture of authentication concepts for the electronics industry and dyes for the textile industry. The chemical division of Yuhan aims to implement sustainable production methods to develop more environmentally-friendly solutions for the industry. In summary, Yuhan Corp is a diverse company that operates in various sectors. The company has enhanced its strategies in research and development, product development, and marketing to strengthen its presence in the global market. With a combination of expertise, technological innovation, and a commitment to sustainability, Yuhan Corp has solidified its status as a leading company in the industry and will continue to do so.
The expected revenue of Yuhan is 2.33 T KRW. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Yuhan is 156.10 B KRW. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Yuhan is currently 32.81. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Yuhan stock.
The price-to-sales ratio (P/S) of Yuhan is currently 2.20. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Yuhan stock.
The Eulerpool Quality Score for Yuhan is 7/10.
The ISIN of Yuhan is KR7000100008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Yuhan is 000100.KS. The ticker symbol is used to trade Yuhan shares on the stock exchange.
Yuhan stock
Yuhan Ticker
Yuhan FIGI
All fundamentals and in-depth analysis of Yuhan
Our stock analysis for Yuhan stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Yuhan. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.